---
title: "Journey Medical Corporation (DERM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DERM.US.md"
symbol: "DERM.US"
name: "Journey Medical Corporation"
industry: "Pharmaceuticals"
datetime: "2026-05-22T00:01:44.726Z"
locales:
  - [en](https://longbridge.com/en/quote/DERM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DERM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DERM.US.md)
---

# Journey Medical Corporation (DERM.US)

## Company Overview

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [journeymedicalcorp.com](https://journeymedicalcorp.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: C (0.49)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 88 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.00% |  |
| Net Profit YoY | -15.48% |  |
| P/B Ratio | 5.51 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 169888154.99 |  |
| Revenue | 64680000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -36.61% | E |
| Profit Margin | -14.82% | D |
| Gross Margin | 61.04% | A |
| Revenue YoY | 15.00% | B |
| Net Profit YoY | -15.48% | D |
| Total Assets YoY | 7.74% | B |
| Net Assets YoY | 43.13% | A |
| Cash Flow Margin | 69.88% | C |
| OCF YoY | 15.00% | B |
| Turnover | 0.73 | B |
| Gearing Ratio | 66.32% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Journey Medical Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-15.48%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.51",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "169888154.99",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "64680000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-36.61%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-14.82%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "61.04%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "15.00%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-15.48%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.74%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "43.13%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "69.88%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "15.00%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.73",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "66.32%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -17.72 | 206/190 | - | - | - |
| PB | 5.51 | 152/190 | 10.18 | 8.33 | 7.48 |
| PS (TTM) | 2.63 | 71/190 | 3.88 | 3.36 | 2.88 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.21 |
| Highest Target | 16.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DERM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DERM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/DERM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/DERM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**